Yahoo
NasdaqGS - Delayed Quote USD

Arbutus Biopharma Corporation (ABUS)

4.3150 +0.1150 (+2.74%)
At close: 3:59:55 PM EDT
4.3200 +0.0050 (+0.12%)
After hours: 4:04:52 PM EDT
Trade ABUS on Coinbase
Chart Range Bar
Loading chart for ABUS
  • Previous Close 4.2000
  • Open 4.2000
  • Bid 4.2800 x 1200
  • Ask 4.3500 x 1200
  • Day's Range 4.1650 - 4.3350
  • 52 Week Range 2.9400 - 5.1000
  • Volume 775,874
  • Avg. Volume 2,427,425
  • Market Cap (intraday) 849.795M
  • Beta (5Y Monthly) 0.74
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1700
  • Earnings Date (est.) May 13, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.25

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

www.arbutusbio.com

19

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: ABUS

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ABUS
10.29%
S&P 500 (^GSPC)
5.62%

1-Year Return

ABUS
19.53%
S&P 500 (^GSPC)
29.01%

3-Year Return

ABUS
71.23%
S&P 500 (^GSPC)
73.47%

5-Year Return

ABUS
24.35%
S&P 500 (^GSPC)
72.92%

Earnings Trends: ABUS

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 1.44M
Earnings --

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-30M
-20M
-10M
0
10M

Analyst Insights: ABUS

View More

Analyst Price Targets

5.03
5.25 Average
4.3150 Current
5.63 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 11/14/2025
Analyst Chardan Capital
Rating Action Maintains
Rating Buy
Price Action Maintains
Price Target 5 -> 5

Statistics: ABUS

View More

Valuation Measures

Annual
As of 4/30/2026
  • Market Cap

    827.15M

  • Enterprise Value

    736.42M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    57.14

  • Price/Book (mrq)

    10.80

  • Enterprise Value/Revenue

    52.29

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -237.88%

  • Return on Assets (ttm)

    -14.94%

  • Return on Equity (ttm)

    -38.52%

  • Revenue (ttm)

    14.08M

  • Net Income Avi to Common (ttm)

    -33.5M

  • Diluted EPS (ttm)

    -0.1700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    91.47M

  • Total Debt/Equity (mrq)

    5.47%

  • Levered Free Cash Flow (ttm)

    -17.62M

Compare To: ABUS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: ABUS

Fair Value

4.3150 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: